The Lead Investor Call

The Scenario Is Just the Vehicle

A whistleblower report names the CEO two days before an acquisition closes.

What This Lab Is Really About

Whether a board can govern when the alleged wrongdoer is the CEO depends on — under deal pressure, against the clock, with a fiduciary duty that points the opposite way from the transaction everyone wants to close.

The real discussion is not about one executive’s conduct. It is about who investigates when the subject is the CEO, what the board must disclose to the buyer right now, whether “investigate after close” is prudent or fraudulent, and whether the company can function if the CEO has to go.

This Is Not a Debate About Whether the CEO Is Guilty

The Lab assumes the report has landed, is credible, and is documented. It never tries the CEO.

Guilt or innocence is for the investigation. The pressure lies in the board’s duty right now: who investigates when the subject is the CEO, what must be disclosed to the buyer before signing, whether pausing or killing the deal is the board’s call to make — and the fact that the company has to function on Monday regardless. The exercise is built so no director in the room is the villain; the failure mode is a board that lets a deal calendar make its fiduciary decision for it.

Inject 1 · The Report

A credible, documented report naming the CEO hits the audit committee and HR channel 48 hours before signing. The board (minus the CEO) convenes. The first instinct is to treat it as a discreet HR matter to be handled quietly.

Inject 2 · The Calendar

The deal is the company’s defining outcome, and the timeline is fixed. The pull is strong: “The allegation is unproven; we can’t tank the valuation over it — close now, investigate after.” This is the trap closing. The room is meant to drift toward pushing the transaction through and looking into it later.

Inject 3 · Fraud on the Buyer (the detonator)

Counsel reframes “investigate later.” Signing while knowingly sitting on a credible, documented allegation of fraud against the CEO is not neutral — it can itself constitute a material fraud on the buyer and a serious disclosure problem. The delay the room was reaching for is the exposure.

And the incentives now cut hard. Under current Department of Justice policy, the internal report has started a limited window in which the company can investigate and self-report and still earn leniency — so chilling, delaying, or burying the report is self-defeating and pushes the whistleblower straight to the government, with an award waiting. The acquirer has its own protection for misconduct it discovers and discloses, meaning a buyer who finds it later is shielded, while a seller who buried it is exposed. The board’s real work begins: stand up a special committee that excludes the CEO, decide on pause-versus-kill, meet the disclosure obligation, and have an emergency succession plan ready — without doing anything that chills the report.

“We’d never cover for a CEO committing fraud.”

No board says that. They say: “Let’s not derail a transformational deal over an unproven allegation — we’ll look into it right after close.” That sentence, said with a credible, documented report already in hand, is how a board backs into a fraud on the buyer. The exposure is the silence and the delay, not anyone’s intent to protect a wrongdoer.

Board Chair — owns the governance process and the relationship with the CEO, now under investigation, and must lead a board that can’t rely on its usual center of gravity.

General Counsel — carries the disclosure obligation, the fraud-on-the-buyer exposure, the self-report calculus and its clock, and the rule against chilling the report.

CHRO — owns the integrity of the report and the protection of the whistleblower and any subordinate involved, and the message the company’s handling sends to every future reporter.

CFO — weighs the valuation, the financial self-dealing allegation against the books, and what a pause or a collapse does to the company and the deal.

Lead Independent Director — the natural special-committee chair: independent of management, owns the credibility of an investigation that the buyer and regulators will scrutinize.

Who Investigates the CEO

Is there a standing mechanism — an independent special committee — for investigating the CEO, or does the board improvise it under deal pressure with the clock running?

What Must We Disclose Now

What is the board’s disclosure obligation to the buyer before signing — and what does signing while knowing actually risk?

Have We Chilled the Report

Has anything the company has done discouraged, delayed, or retaliated against the report — now self-defeating, since the report itself starts the clock that preserves the company’s options?

Can the Company Run Without the CEO

Is there an emergency succession plan, or is the company’s dependence on this one person itself the governance failure the deal would have inherited?

0–10 min — Frame. The report has landed and is credible; the CEO is out of the room; we decide the board’s duty, not the CEO’s guilt.

10–30 min — Inject 1. The report arrives. The “quiet HR matter” instinct surfaces.

30–50 min — Inject 2. The calendar pressure. Let the room drift toward “close now, investigate later.”

50–70 min — Inject 3. Fraud on the buyer, the self-report clock, the chilling trap, the acquirer’s protection. The reckoning.

70–90 min — Reframe & commit. The surfacing questions, then the decisions the board carries out — special-committee trigger, disclosure posture, pause-vs-kill mechanics, emergency succession.

Facilitator’s guide — run-of-show, timing, the rule of the room, and how to keep it on the board’s duty rather than trying the CEO.

The three inject cards — sequenced for timed reveal, with Inject 3 (fraud on the buyer) held as the detonator.

Role briefs — one per seat (Board Chair, General Counsel, CHRO, CFO, Lead Independent Director), each with the pressure that seat carries.

Reframe & surfacing-question set — the “we’d never cover for a fraudulent CEO” turn and the four questions to leave open.

Governance & legal-context primer — plain-language, counsel-hedged: board and audit-committee fiduciary duty, the independent special committee excluding the implicated CEO, materiality and the disclosure obligation to the buyer, why “close now / investigate later” can be a fraud on the buyer, the current DOJ self-report window that the internal report opens, the rule against chilling a report, and the acquirer’s diligence-disclosure protection.

Commitments template — the special-committee trigger and charter, the disclosure decision framework, pause-vs-kill mechanics, the whistleblower-protection check, and the emergency-succession plan.

Debrief one-pager — the takeaways and the homework, sized for a follow-up to the board.

Part of the Executive Decision Lab™ line. Each Lab puts a leadership team inside a high-pressure decision where the right answer is obvious in principle and hard in practice. Explore the full line of Executive Decision Labs.